Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
RAMELTEON (UNII: 901AS54I69) (RAMELTEON - UNII:901AS54I69)
Carilion Materials Management
RAMELTEON
RAMELTEON 8 mg
ORAL
PRESCRIPTION DRUG
ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6-week studies (adults and elderly), and at the end of the 6-month study (adults and elderly) [see Clinical Studies (14)] . Patients who develop angioedema after treatment with ROZEREM should not be rechallenged with the drug. Patients should not take ROZEREM in conjunction with fluvoxamine (Luvox) [see Drug Interaction (7)] . Pregnancy Category C In animal studies, ramelteon produced evidence of developmental toxicity, including teratogenic effects, in rats at doses much greater than the recommended human dose (RHD) of 8 mg/day. There are no adequate and well-controlled studies in pregnant women. ROZEREM should be used during pregnancy only if the potential benefit justifies the pote
Product: 68151-4881 NDC: 68151-4881-1 1 TABLET, FILM COATED in a BLISTER PACK
New Drug Application
Carilion Materials Management ---------- MEDICATION GUIDE ROZEREM (rō-Zair-em) (ramelteon) Read the Medication Guide that comes with ROZEREM before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. What is the most important information I should know about ROZEREM? ROZEREM may cause severe allergic reactions. Symptoms include swelling of the tongue or throat, trouble breathing, and nausea and vomiting. Get emergency medical help if you get these symptoms after taking ROZEREM. After taking ROZEREM, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with ROZEREM. Activities may include: • driving a car ("sleep-driving") • making and eating food • talking on the phone • having sex • sleep-walking Call your doctor right away if you find out that you have done any of the above activities after taking ROZEREM. Important: 1. Take ROZEREM exactly as prescribed • Do not take more ROZEREM than prescribed. • Take ROZEREM within 30 minutes of going to bed, not sooner. 2. Do not take ROZEREM if you: • drink alcohol • take other medicines that can make you sleepy. Talk to your doctor about all of your medicines. Your doctor will tell you if you can take ROZEREM with your other medicines • cannot get a full night's sleep WHAT IS ROZEREM? ROZEREM is a hypnotic (sleep) medicine. ROZEREM is used in adults for the treatment of the symptom of trouble falling asleep from insomnia. ROZEREM is not for children. Who should not take ROZEREM? Do not take ROZEREM if you are allergic to anything in it. See the end of this Medication Guide for a complete list of ingredients in ROZEREM. Do not take ROZEREM if you are currently Perskaitykite visą dokumentą
ROZEREM- RAMELTEON TABLET, FILM COATED CARILION MATERIALS MANAGEMENT ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ROZEREM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ROZEREM. ROZEREM (RAMELTEON) TABLETS INITIAL U.S. APPROVAL: 2005 INDICATIONS AND USAGE ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. (1) DOSAGE AND ADMINISTRATION Adult dose: 8 mg taken within 30 minutes of going to bed. (2.1) Should not be taken with or immediately after a high-fat meal. (2.1) Total daily dose should not exceed 8 mg. (2.1) DOSAGE FORMS AND STRENGTHS 8 mg tablets. (3) CONTRAINDICATIONS History of angioedema while taking ROZEREM. (4) Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (7.1) WARNINGS AND PRECAUTIONS Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur. (5.1) Need to evaluate for co-morbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment. (5.2) Abnormal thinking, behavioral changes, complex behaviors: May include "sleep-driving" and hallucinations. Immediately evaluate any new onset behavioral changes. (5.3) Depression: Worsening of depression or suicidal thinking may occur. (5.3) CNS effects: Potential impairment of activities requiring complete mental alertness such as operating machinery or driving a motor vehicle, after ingesting the drug. (5.4) Reproductive effects: Include decreased testosterone and increased prolactin levels. Effect on reproductive axis in developing humans is unknown. (5.5) Patients with severe sleep apnea: Rozerem is not recommended for use in this population. (5.6) ADVERSE REACTIONS Most common adverse reactions (≥3% and more common than with placebo) are: somnolence, dizziness, fatigue, nausea, and exacerbated insomnia. (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT TAKEDA PHARMACEUTICALS A Perskaitykite visą dokumentą